Assignee
STARTON THERAPEUTICS INC
US·5 granted patents·6 pending applications·4 citations·filing 2019–2024
Top patents by PatentIndex Score
11 records- 0190US11197852B2Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2020·Granted Dec 14, 2021·4 cites·18 claims
- 0279US12383510B2Treatment of vomiting and nausea with minimum dose of olanzapineSTARTON THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·19 claims
- 0376US2025108043A1Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0469US12201622B2Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2021·Granted Jan 21, 2025·0 cites·18 claims
- 0564US11975112B2Treatment of vomiting and nausea with minimum dose of olanzapineSTARTON THERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·11 claims
- 0660US2025134828A1Molecular solid suspensions for transdermal drug deliverySTARTON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0756US2021100737A1Transdermal delivery of dronabinolSTARTON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0855US2022395468A1Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory AgentsSTARTON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0954US2024009204A1Treatment of Vomiting and Nausea with Minimum Dose of OlanzapineSTARTON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1053US12390457B2Stable solutions of immunomodulatory imide compounds for parenteral useSTARTON THERAPEUTICS INC·Filed 2022·Granted Aug 19, 2025·0 cites·6 claims
- 1152US2022040194A1Use of olanzapine for treatment of parp-inhibitor-induced nauseaSTARTON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →